A065650 Stock Overview
Medifron DBT Co., Ltd., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Medifron DBT Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,445.00 |
| 52 Week High | ₩2,565.00 |
| 52 Week Low | ₩920.00 |
| Beta | 0 |
| 1 Month Change | -6.77% |
| 3 Month Change | 47.30% |
| 1 Year Change | 12.02% |
| 3 Year Change | -61.77% |
| 5 Year Change | -72.26% |
| Change since IPO | -51.83% |
Recent News & Updates
Shareholder Returns
| A065650 | KR Electronic | KR Market | |
|---|---|---|---|
| 7D | 13.0% | 3.3% | 2.2% |
| 1Y | 12.0% | -20.8% | 5.4% |
Return vs Industry: A065650 exceeded the KR Electronic industry which returned -20.8% over the past year.
Return vs Market: A065650 exceeded the KR Market which returned 5.4% over the past year.
Price Volatility
| A065650 volatility | |
|---|---|
| A065650 Average Weekly Movement | 11.4% |
| Electronic Industry Average Movement | 5.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A065650's share price has been volatile over the past 3 months.
Volatility Over Time: A065650's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Hyun-Sang Muk | www.medifron.com |
Medifron DBT Co., Ltd., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and wheels; keyboards; headsets; webcams; and sound bars, as well as provides online contents.
Medifron DBT Co., Ltd. Fundamentals Summary
| A065650 fundamental statistics | |
|---|---|
| Market cap | ₩91.26b |
| Earnings (TTM) | -₩3.52b |
| Revenue (TTM) | ₩31.41b |
0.0x
P/S Ratio0.0x
P/E RatioIs A065650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A065650 income statement (TTM) | |
|---|---|
| Revenue | ₩31.41b |
| Cost of Revenue | ₩27.16b |
| Gross Profit | ₩4.25b |
| Other Expenses | ₩7.78b |
| Earnings | -₩3.52b |
Last Reported Earnings
Dec 31, 2020
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A065650 perform over the long term?
See historical performance and comparison